Claus S. Garbe

Claus S. Garbe

Hoppe Seyler Str. 3
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 431 publications

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 19, 2026

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 19, 2026

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Journal: Journal for immunotherapy of cancer

Published: November 30, 2025

Improvement of overall survival in patients with cutaneous melanoma at a tertiary care center in Germany from 2001 to 2020.

Improvement of overall survival in patients with cutaneous melanoma at a tertiary care center in Germany from 2001 to 2020.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: October 24, 2025

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 10, 2025

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 23, 2025

Cutaneous squamous cell carcinoma 1986-2019 in Germany: Incidence, anatomical site, staging, and histologic subtypes.

Cutaneous squamous cell carcinoma 1986-2019 in Germany: Incidence, anatomical site, staging, and histologic subtypes.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 11, 2025

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Journal: Nature communications

Published: July 24, 2025

Messages for ultraviolet-radiation protection to fair-skinned populations.

Messages for ultraviolet-radiation protection to fair-skinned populations.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: May 28, 2025

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation.

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation.

Journal: Frontiers in oncology

Published: April 26, 2025

Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma.

Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma.

Journal: International journal of molecular sciences

Published: April 14, 2025

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 31, 2025

Showing 1-12 of 431

Last Updated: 09/26/2026